Evidence map›Paper›PMID 25812085›Full record

SynthesisPloS one2015

Prophylactic use of macrolide antibiotics for the prevention of chronic obstructive pulmonary disease exacerbation: a meta-analysis.

Wentao Ni, Xiaodi Shao, Xuejiu Cai, Chuanqi Wei, Junchang Cui, Rui Wang, Youning Liu

Open access · goldAbstract readMeta-Analysis
In one paragraph

Synthesis in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed, 7 pooled it
10.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 7 syntheses or guidelines pooled it, 107 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Romanian clinical guideline for diagnosis and treatment of COPD.The Journal of international medical research · 2020
    Guideline
  4. Pooled it
  5. Pooled it
  6. Effects of long-term macrolide therapy at low doses in stable COPD.International journal of chronic obstructive pulmonary disease · 2019
    Pooled it
  7. Pooled it
  8. Trial
  9. Review
  10. Review
  11. Review
  12. Exploiting haem-iron dependence of nontypeableFrontiers in cellular and infection microbiology · 2025
    Review
  13. Review
  14. Review
  15. Observational
  16. Article
  17. Article
  18. COPD - do the right thing.BMC family practice · 2021
    Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Wentao NiDepartment of Respiratory Diseases, Chinese People's Liberation Army General Hospital, Beijing, China.
Xiaodi ShaoDepartment of Respiratory Diseases, Chinese People's Liberation Army General Hospital, Beijing, China.
Xuejiu CaiDepartment of Respiratory Diseases, Chinese People's Liberation Army General Hospital, Beijing, China.
Chuanqi WeiDepartment of Respiratory Diseases, Chinese People's Liberation Army General Hospital, Beijing, China.
Junchang CuiDepartment of Respiratory Diseases, Chinese People's Liberation Army General Hospital, Beijing, China.
Rui WangDepartment of Clinical Pharmacology, Chinese People's Liberation Army General Hospital, Beijing, China.
Youning LiuDepartment of Respiratory Diseases, Chinese People's Liberation Army General Hospital, Beijing, China.
Chinese People's Liberation Army · CNPeople's Liberation Army No. 150 Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAcute exacerbations of chronic obstructive pulmonary disease (AECOPDs) can lead to high frequencies and rates of hospitalization and mortality. Macrolides are a class of antibiotics that possess both antimicrobial and anti-inflammatory properties. Since the occurrence of AECOPDs is associated with aggravation of airway inflammation and bacterial infections, prophylactic macrolide treatment may be an effective approach towards the prevention of AECOPDs.

methodsWe systemically searched the PubMed, Embase and Cochrane Library databases to identify randomized controlled trials (RCTs) that evaluated the effect of prophylactic macrolide therapy on the prevention of AECOPDs. The primary outcomes were the total number of patients with one or more exacerbations as well as the rate of exacerbations per patient per year.

resultsNine RCTs comprising 1666 patients met the inclusion criteria. Pooled evidence showed macrolides could reduce the frequency of exacerbations in patients with COPD by both unweighted (RR = 0.70; 95% CI: 0.56-0.87; P < 0.01) and weighted approaches (RR = 0.58, 95% CI: 0.43-0.78, P < 0.01). Subgroup analysis showed only 6-12 months of erythromycin or azithromycin therapy could be effective. Moreover, among studies with 6-12 months of azithromycin therapy, both the daily dosing regimen and the intermittent regimen significantly reduced exacerbation rates. The overall number of hospitalizations and the all-cause rate of death were not significantly different between the treatment and control groups. A tendency for more adverse events was found in the treatment groups (OR = 1.55, 95%CI: 1.003-2.39, P = 0.049).

conclusionsOur results suggest 6-12 months erythromycin or azithromycin therapy could effectively reduce the frequency of exacerbations in patients with COPD. However, Long-term treatment may bring increased adverse events and the emergence of macrolide-resistance. A recommendation for the prophylactic use of macrolide therapy should weigh both the advantages and disadvantages.

Indexed as

Antibiotic ProphylaxisBacterial InfectionsDisease ProgressionHumansInflammationMacrolidesOdds RatioPublication BiasPulmonary Disease, Chronic ObstructiveTreatment OutcomeMacrolides

Identifiers

PMID25812085
PMCPMC4374882
OpenAlexW2007903763

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.